Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Summit Therapeutics and Lunit announced a research agreement to apply Lunit's AI-powered SCOPE IO pathology platform to tumor microenvironment analysis in support of Summit's ivonescimab immuno-oncology development programs. The work will use H&E whole-slide images to support biomarker discovery, patient stratification, and a deeper biological understanding of response to ivonescimab, Summit's PD-1/VEGF bispecific antibody in multiple Phase III trials.
Key figures
- Summit sponsored phase3
- 5
- Phase3 studies ivonescimab
- 17
- Patients treated clinical studies
- 5000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.